Bright peak therapeutics

Index
Globenewswire

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Globenewswire

Bright Peak Therapeutics to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Globenewswire

Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Globenewswire

Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate